Oncology
Cancer clinical trials
Studies of cancers and tumors of every type and site, from prevention to treatment. We’re tracking 20,602 recruiting studies in this area right now.
By phase
- Not applicable9,790
- Phase 24,449
- Phase 12,736
- Phase 1/Phase 21,687
- Phase 31,397
- Phase 2/Phase 3280
- Phase 4263
Top conditions
- Breast Cancer1,227
- Cancer661
- Prostate Cancer654
- Colorectal Cancer491
- Lung Cancer424
- Ovarian Cancer338
- Multiple Myeloma332
- Gastric Cancer296
- Acute Myeloid Leukemia292
- Pancreatic Cancer290
- Hepatocellular Carcinoma283
- Solid Tumor257
- Advanced Solid Tumor255
- Cervical Cancer232
- Head and Neck Cancer227
- Endometrial Cancer206
- Advanced Solid Tumors193
- Esophageal Cancer191
Leading sponsors
- M.D. Anderson Cancer Center450
- Fudan University313
- Sun Yat-sen University290
- Memorial Sloan Kettering Cancer Center288
- National Cancer Institute (NCI)285
- Mayo Clinic240
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences151
- City of Hope Medical Center147
- AstraZeneca134
- University Health Network, Toronto125
Where studies are running
- California1,424
- Texas638
- Arizona513
- Florida448
- Alabama420
- New York409
- Massachusetts343
- Maryland329
- New Jersey269
- Pennsylvania241
Recruiting studies20,602 total
- NCT06995105RecruitingPhase 1/Phase 2
Personalized mRNA Vaccine for Advanced Liver Cancer
This trial tests a personalized mRNA vaccine made from your tumor's unique genetic markers. It is for people with advanced liver cancer who have not yet received any treatment.
Hangzhou, ZhejiangAges 18–75 - NCT06397963Recruiting
Personalized immune cell therapy for advanced solid tumors
This study tests a new treatment using your body's own immune cells (called tumor-infiltrating lymphocytes) that are taken from your tumor, grown in a lab, and then put back into you. It's for people with advanced solid tumors who have run out of standard options.
Beijing, Beijing MunicipalityAges 18–70 - NCT06650332RecruitingPhase 1/Phase 2
Cadonilimab combo for first-line HER2-positive gastric cancer
This trial tests a new combination treatment (cadonilimab plus chemotherapy) as the first therapy for people with advanced gastric or gastroesophageal junction cancer that has a certain amount of HER2 protein. It aims to see if this combination can shrink tumors and help people live longer.
Hangzhou, ZhejiangAges 18–75 - NCT07081269Recruiting
Fitness and thinking skills in Alzheimer's risk
This study looks at how physical fitness relates to thinking skills (like planning and focus) in people who may be at risk for Alzheimer's. You would do some simple fitness tests and thinking tasks to help researchers understand if staying fit can protect your brain.
TaipeiAges 50–70 - NCT04982276RecruitingPhase 1/Phase 2
Test new cancer drugs for advanced stomach or esophagus cancer
This Phase 1/2 study tests the safety and effectiveness of two investigational drugs (AK109 and AK104) in people with advanced stomach (or lower esophagus/GEJ) cancer. It’s for cases where the cancer did not respond to first-line treatment that included anti–PD-1/PD-L1 therapy plus chemotherapy.
BeijingAges 18–75 - NCT06934538RecruitingPhase 1/Phase 2
Immunotherapy trial for advanced colorectal cancer
This trial tests a new immunotherapy drug (STC-1010) for people with colorectal cancer that cannot be removed by surgery or has spread. It aims to see if the drug can shrink tumors or slow the disease.
Baltimore, MarylandAges 18–75 - NCT05985278RecruitingEarly Phase 1
Lutetium-177 catalase injection for advanced solid tumors
This trial tests a new radioactive drug (Lutetium-177 attached to an enzyme called catalase) that is injected directly into tumors. It is for people with advanced solid tumors, like liver, ovarian, or prostate cancer, who have run out of standard treatment options.
Beijing, Beijing MunicipalityAges 18–70 - NCT07586215Recruiting
HER2-targeted PET imaging to predict treatment response in advanced breast cancer
This trial tests whether a special type of PET scan can predict how well a targeted cancer drug (T-DXd) will work for patients with advanced breast cancer that has specific HER2 markers. The goal is to help doctors personalize treatment decisions based on imaging results.
ShanghaiAges 18 years+ - NCT06682390Recruiting
Race and diet study for men on hormone therapy
This study explores how race affects nutrition for men receiving hormone therapy (ADT) for prostate cancer. It may help researchers understand if different dietary approaches are needed based on race.
Los Angeles, CaliforniaAges 18 years+ - NCT06401603RecruitingPhase 1
Study of three drugs for advanced CML and Ph+ AML
This trial tests a combination of three drugs (decitabine, lisaftoclax, and olverembatinib) for people with advanced chronic myeloid leukemia or Philadelphia chromosome-positive acute myeloid leukemia who have not responded to or could not tolerate previous treatments.
Houston, TexasAges 18 years+ - NCT06644300RecruitingPhase 1
Study of BM230 for advanced solid tumors with HER2
This trial tests a new drug called BM230 for people with advanced solid tumors that have HER2 protein or gene changes. It aims to see if the drug is safe and effective for those who have run out of standard treatment options.
Brisbane, QueenslandAges 18 years+ - NCT06405945Recruiting
Cervical cancer risk study for average-risk adults
This study aims to better understand who is most likely to develop cervical cancer. It uses a simple blood test and follow-up during colposcopy to improve screening for people at average risk.
Hefei, AnhuiAges 18 years+ - NCT06402201RecruitingPhase 1
First human trial of CDR404 for MAGE-A4 positive solid tumors
This trial tests an experimental treatment called CDR404 for people with certain advanced solid tumors. It is designed for those whose tumors have a specific protein (MAGE-A4) and who have already tried other treatments. The goal is to see if the treatment is safe and effective.
Miami, FloridaAges 18 years+ - NCT07028073RecruitingPhase 1/Phase 2
New targeted treatment for newly diagnosed CBF-AML with KIT mutation
This trial tests a new targeted therapy for a specific type of leukemia (CBF-AML with a KIT gene change) in people who have not yet had treatment. The goal is to see if adding a KIT inhibitor to standard chemotherapy can improve outcomes.
Suzhou, JiangsuAges 18 years+ - NCT06082934RecruitingPhase 1/Phase 2
Triple drug combo for newly diagnosed Ph+ ALL
This trial tests a combination of three targeted drugs (olverembatinib, venetoclax, and dexamethasone) for people newly diagnosed with a specific type of leukemia called Ph+ ALL. The goal is to see if this combination can help control the disease without needing traditional chemotherapy.
Xi'an, ShannxiAges 18 years+ - NCT06404281RecruitingPhase 1
Modified immune cells for advanced solid tumors
This trial tests a new type of immune cell therapy (gamma-delta T cells that have been modified to target PD-1) for people with advanced solid tumors that have not responded to standard treatments. The goal is to see if these cells can help your immune system fight the cancer.
ChangzhouAges 18–80 - NCT06405217Recruiting
Recombinant TSH for radioactive iodine therapy in thyroid cancer
This trial tests whether a medicine called recombinant human thyroid stimulating hormone (rhTSH) can help prepare your body for radioactive iodine (131I) treatment, which aims to destroy any remaining or spreading thyroid cancer cells. It may be a good option if your thyroid cancer has come back or spread and you are able to have radioactive iodine therapy.
Nanjing, JiangsuAges 18–75 - NCT07077434RecruitingPhase 1
Study of Navlimetostat for advanced solid tumors with specific gene change
This trial tests a new drug, Navlimetostat (BMS-986504), for people with advanced solid tumors that have a specific genetic change called MTAP deletion or loss. It looks at safety, side effects, and how the drug works in the body.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07544784RecruitingPhase 2
AK104 plus radiation for colorectal cancer spread to liver
This study tests a new immunotherapy drug called AK104 combined with radiation therapy and standard chemotherapy for colorectal cancer that has spread to the liver. The goal is to see if adding AK104 and targeted radiation improves treatment outcomes compared to standard therapy alone.
ShanghaiAges 18 years+ - NCT06995157Recruiting
HPV infections and vaccine attitudes in Slovenian women
This observational study looks at HPV infections and women's views about the HPV vaccine in Slovenia. It aims to understand the characteristics of HPV infections and attitudes toward vaccination after the vaccine became available.
Ljubljana, Municipality of DomžaleAges Up to 35 years - NCT05753306RecruitingPhase 2
Robot surgery plus heated chemo for limited spread stomach cancer
This study tests a “robot-assisted” surgery to remove stomach cancer in the belly lining (peritoneum) along with heated chemotherapy placed inside the abdomen. It’s for people whose cancer has spread only in the peritoneum, aiming to control disease when there’s a good chance of removing it all.
Rochester, MinnesotaAges 18–80 - NCT07142967Recruiting
MR-Linac radiotherapy for prostate cancer that returned after earlier radiation
This trial tests if a special MRI-guided radiotherapy machine (MR-Linac) can safely treat prostate cancer that has come back after previous radiation therapy. It may help men who have limited options and want to avoid more invasive treatments.
New York, New YorkAges 18 years+ - NCT06986785RecruitingPhase 2
Study of new drug combinations for advanced liver cancer
This trial tests a new drug called BL-B01D1, alone or together with other drugs, in people with advanced liver cancer that has not improved with other treatments. The goal is to see if these combinations can help shrink tumors or slow the cancer's growth.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT06974812RecruitingPhase 1/Phase 2
Study of IBI3014 for advanced solid tumors
This trial tests a new drug called IBI3014 for people with advanced solid tumors that cannot be removed by surgery. It aims to see if the drug is safe and effective.
Fuzhou, FujianAges 18 years+
Common questions
- How many cancer clinical trials are recruiting?
- Clin2 is tracking 20,602 recruiting oncology studies from the U.S. registry right now, out of 31,289 we cover in this area in total.
- What does “Cancer” cover here?
- Studies of cancers and tumors of every type and site, from prevention to treatment. We group each study into cancer based on the conditions it studies, so you can scan the whole therapeutic area at once and drill into a specific condition.
- How do I find a cancer trial near me?
- Use the search to filter cancer studies by location and eligibility. Every Clin2 trial page explains the criteria in plain English and offers a short, optional pre-screen for a fit read — the study team makes the final decision.
Other specialties
- Brain & nervous system
- Heart & circulation
- Hormones & metabolism
- Mental health
- Digestive system
- Lungs & breathing
- Immune system & allergy
- Women’s health & pregnancy
- Skin
- Blood & lymphatic
- Kidney & urinary
- Infections
- Genetic & congenital
- Bones, joints & muscles
- Pain
- Injuries & trauma
- Mouth & dental
- Eyes & vision
- Ear, nose & throat
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov; specialty groupings are derived from each study’s conditions. Talk with your doctor about whether a specific trial is right for you.